Postmarket policy considerations for biosimilar oncology drugs.
about
Improving access to high-cost cancer drugs in Latin America: Much to be done.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesSex differences in the risk of receiving potentially inappropriate prescriptions among older adultsKey drivers for market penetration of biosimilars in Europe.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Biosimilar biologic drugs: a new frontier in medical care.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Policies for biosimilar uptake in Europe: An overview.Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
P2860
Q30235988-48F278EB-8B7C-4B73-A8C9-BCBA15833F72Q33665611-13B6549C-54B2-45ED-AF49-FAECD4A9A87BQ37027232-2A13DF82-DE95-46D0-A080-37F528564059Q37669625-E89C93F4-221C-4B6A-9673-9BEDC753515CQ38708927-D04FB91D-EBC5-4DEE-9103-A9A7B9E7AEA1Q39016810-C2D8F9C0-92C3-4EFC-A8D5-30CB60A86CB5Q39072439-5220BC00-F7FA-434A-A314-CFBD800C96E9Q39200937-9AEB8867-089F-403B-9F72-3F5B702118D1Q39455869-2B58481E-D1B7-49AC-80AA-35C28E6CC338Q40995361-A81E1281-54D7-4868-BE66-7646712596FBQ47173303-E27D38DB-63D4-4BA4-A87F-010D5908AA03Q47706731-8E4822FA-45B6-4D4A-BD24-D39776466618Q57173064-2D026326-645C-4D99-A580-0383EBBCE9A0
P2860
Postmarket policy considerations for biosimilar oncology drugs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Postmarket policy considerations for biosimilar oncology drugs.
@en
type
label
Postmarket policy considerations for biosimilar oncology drugs.
@en
prefLabel
Postmarket policy considerations for biosimilar oncology drugs.
@en
P2093
P1433
P1476
Postmarket policy considerations for biosimilar oncology drugs.
@en
P2093
Deirdre Weymann
Emilie J Gladstone
Kate Smolina
Matthew J Renwick
Steven G Morgan
P356
10.1016/S1470-2045(15)00381-2
P577
2015-12-23T00:00:00Z